BioMarin Pharma (BMRN) Misses Q1 EPS by 8c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $55.90 +2.21%
EPS Growth %: -34.0%
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -34.0%
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of ($0.26), $0.08 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $373.4 million versus the consensus estimate of $348.57 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Hermès can regain momentum despite China weakness, Jefferies says
- Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
